NCT02564107View on ClinicalTrials.gov

A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions
Pain; Bone Neoplasms; Neoplasm Metastasis
Interventions
DRUG

Ibandronate

Participants will receive ibandronate, 50 milligrams (mg) by mouth every morning, for a period of 25 weeks.

Trial Locations (8)

1527

Sofia

1756

Sofia

1784

Sofia

4004

Plovdiv

5000

Veliko Tarnovo

8000

Stara Zagora

9010

Varna

Unknown

Shumen

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02564107 - A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease | Biotech Hunter | Biotech Hunter